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1358in the treatment of allergic diseases, and hence understanding
their interaction is likely to have clinical implications.
Objective: We aimed to comprehensively define the roles of
PGD2, LTE4, and their combination in activating human TH2
cells and how such activation might allow the TH2 cells to
engage downstream effectors, such as neutrophils, which
contribute to the pathology of allergic responses.
Methods: The effects of PGD2, LTE4, and their combination on
human TH2 cell gene expression were defined by using a
microarray, and changes in specific inflammatory pathways
were confirmed by means of PCR array, quantitative RT-PCR,
ELISA, Luminex, flow cytometry, and functional assays,
including analysis of downstream neutrophil activation.
Blockade of PGD2 and LTE4 was tested by using TM30089, an
antagonist of chemoattractant receptor-homologous molecule
expressed on TH2 cells, and montelukast, an antagonist of
cysteinyl leukotriene receptor 1.
Results: PGD2 and LTE4 altered the transcription of a wide
range of genes and induced diverse functional responses in TH2
cells, including cell adhesion, migration, and survival and
cytokine production. The combination of these lipids
synergistically or additively enhanced TH2 responses and,
strikingly, induced marked production of diverse nonclassical
TH2 inflammatory mediators, including IL-22, IL-8, and GM-
CSF, at concentrations sufficient to affect neutrophil activation.
Conclusions: PGD2 and LTE4 activate TH2 cells through
different pathways but act synergistically to promote multiple
downstream effector functions, including neutrophil migration
and survival. Combined inhibition of both PGD2 and LTE4
pathways might provide an effective therapeutic strategy for
allergic responses, particularly those involving interaction
between TH2 cells and neutrophils, such as in patients with
severe asthma. (J Allergy Clin Immunol 2015;135:1358-66.)
Key words: Prostaglandin D2, leukotriene E4, chemoattractant
receptor-homologous molecule expressed on TH2 cells, TH2 cells,
neutrophils
Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs)
are lipid mediators released from mast cells.1 Both are detected
in high concentrations at sites of allergic inflammation, playing
critical roles in the pathogenesis of allergic disorders.2,3
A significant contribution of PGD2 to the development of
allergic inflammation has been suggested by the observation of
enhanced eosinophilic lung inflammation and cytokine release
in transgenic mice overexpressing PGD2 synthase.
4 Two PGD2
receptors have been identified: D prostanoid receptor 1 and
chemoattractant receptor-homologous molecule expressed on
TH2 cells (CRTH2).
5 CRTH2 is highly expressed in human
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 5
XUE ET AL 1359Abbreviations usedCAIA: Cell activation–induced aggregationCRTH2: Chemoattractant receptor-homologous molecule expressed
on TH2 cellscysLT: Cysteinyl leukotrieneCysLT1: Cysteinyl leukotriene receptor 1CysLT2: Cysteinyl leukotriene receptor 2ICAM: Intercellular adhesion moleculeLTC4: Cysteinyl leukotriene C4
LTD4: Cysteinyl leukotriene D4
LTE4: Cysteinyl leukotriene E4
PGD2: Prostaglandin D2
PI3K: Phosphoinositide 3-kinasePMA: Phorbol 12-myristate 13-acetateqPCR: Quantitative PCRRORgt: Retinoic acid–related orphan receptor gteosinophils, basophils, TH2 cells, and group 2 innate lymphoid
cells.6-8 Evidence suggests that the proinflammatory role of
PGD2 in these cells is predominantly mediated by CRTH2.
Through CRTH2, PGD2 elicits chemotaxis,
6,7,9 stimulates type
2 cytokine production,9-11 and suppresses apoptosis.12
CysLTs, including cysteinyl leukotriene C4 (LTC4), cysteinyl
leukotriene D4 (LTD4), and cysteinyl leukotriene E4 (LTE4), are
derived from the 5-lipoxygenase pathway of arachidonic acid
metabolism. Two G protein–coupled receptors for cysLTs have
been characterized and designated as cysteinyl leukotriene recep-
tor 1 (CysLT1) and cysteinyl leukotriene receptor 2 (CysLT2).
13,14
CysLT1 mediates bronchoconstriction and proinflammatory
effects, including activation and migration of leukocytes.15,16
CysLT1 antagonists, including montelukast, are approved for
clinical use in patients with asthma and allergic rhinitis.
We reported recently that cysLTs potentiated type 2 cytokine
production from human TH2 cells in response to PGD2.
17 The
combination of a CRTH2 antagonist and montelukast was
required to completely inhibit type 2 cytokine production induced
by mast cell supernatants. These data highlighted an interaction
between PGD2 and cysLTs in promoting mast cell–mediated
TH2 cell activation. To date, understanding of the synergistic
effects of these lipids on TH2 cell function is limited to type 2
cytokine production. Hence we investigated their effects on
additional mediators of allergic inflammation and their roles in
triggering diverse TH2 cell responses. In particular, we addressed
their ability to crosstalk with neutrophils, which are critical
players in allergic inflammation, particularly in patients with
severe asthma.18,19 Because our previous studies had identified
LTE4 as the most potent cysLT in TH2 cytokine production,
17
we focused on the effects of combining PGD2 and LTE4.
Our data demonstrate that the proinflammatory effects of both
PGD2 and LTE4 in human TH2 cells reach far beyond type 2
cytokine production. Indeed, we find that these lipids synergis-
tically upregulated expression of a range of genes associated
with inflammation and confirm that this gene regulation en-
hances TH2 cell adhesiveness, migration, and survival and pro-
motion of TH2 crosstalk with neutrophils in vitro. Hence we
suggest that the synergistic action of PGD2 and LTE4 could
contribute to neutrophilia in patients with severe asthma by
inducing neutrophil chemokine and growth factor production
by TH2 cells.METHODS
TH2 lymphocytes
TH2 cells were isolated from buffy coats (National Blood Service, Bristol,
United Kingdom), as described in the Methods section in this article’s Online
Repository at www.jacionline.org.11 They are memory cells showing a
CD41CRTH21CD45RO1GATA31CCR62CD45RA2 retinoic acid–related
orphan receptor gt (RORgt)2 phenotype with relatively high purity (see
Fig E1, A, in this article’s Online Repository at www.jacionline.org).
For analysis of gene regulation and cytokine production, TH2 cells were
treated with PGD2 or LTE4 alone or their combination in X-VIVO 15 medium
(Lonza, Basel, Switzerland) in the presence or absence of antagonist
compounds for 2.5 hours (microarray, PCR array, and quantitative PCR
[qPCR]) or 4 hours (Luminex).
Cells were treated with the same compounds in serum-free RPMI medium
for 4 hours to prepare TH2 cell–conditioned media for neutrophil assays.
Neutrophils
Human neutrophils were isolated from fresh whole blood. Briefly, the red
blood cell pellet was collected after Ficoll-Paque Plus density gradient,
suspended in HBSS, and mixed with 3% dextran. Neutrophil-rich supernatant
was collected and treated in a 0.2% NaCl solution for red blood cell lysis and
resuspended in RPMI medium.
Microarrays
Total cellular RNAwas extracted with RNeasy Mini kits (Qiagen, Hilden,
Germany). Microarrays were performed by Cambridge Genomic Services
(Cambridge, United Kingdom) using a HumanHT-12 v4 chip. Genes
significant at a P value of less than .05 were analyzed by using the Venn
Diagram module within GenePattern.20 Pathway analyses were conducted
with IPA (Ingenuity Systems, www.ingenuity.com). Heat maps were
generated by using GENE-E software (http://www.broadinstitute.org/
cancer/software/GENE-E/index.html).
PCR arrays
PCR arrays were performed with an RT2 Profiler PCR Array Human
Common Cytokines kits (SABiosciences, Frederick, Md) in a LightCycler
480 Real-Time PCR System (Roche, Mannheim, Germany).
Luminex
Cytokines were measured with a Procarta Human Cytokine Immunoassay
kit (Affymetrix, Santa Clara, Calif). The results were obtained with a Bio-Plex
200 System (Bio-Rad Laboratories, Hercules, Calif).
qPCR
qPCR was performed, as described previously.17 Primers and probes
(Roche) used are listed in Table E1 in this article’s Online Repository at
www.jacionline.org.
ELISA
Cytokines were assayed with ELISA kits (R&D Systems, Minneapolis,
Minn). The results were measured in a FLUOstar OPTIMA luminescence
plate reader (BMG LabTech, Ortenberg, Germany).
Flow cytometric analysis
Cells were labeled with antibody to CD16–fluorescein isothiocyanate or
Annexin V–allophycocyanin and then acquired with an LSR II Flow
Cytometer (BD Biosciences, San Jose, Calif).
Cell aggregation analysis
Cell aggregation was photographed with a Nikon Eclipse TS100
microscope (Nikon, Tokyo, Japan). Images were analyzed with CellProfiler
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this article’s Online Repository).21Chemotaxis assays
Chemotaxis assays were conducted, as described previously.9Statistics
Data were analyzed by using 1-way ANOVA, followed by the Newman-
Keuls test. P values of less than .05 were considered statistically significant.FIG 1. Gene regulation in TH2 cells by PGD2 and LTE4 detected by using a
microarray. A, Venn diagram representing total numbers of genes
regulated significantly. B, Venn diagrams and heat map showing numbers
of genes downregulated or upregulated significantly. P < .05.RESULTS
Effect of PGD2 and LTE4 on the gene expression
profile of TH2 cells
PGD2 and LTE4 synergistically evoke type 2 cytokine
production from human TH2 cells.
17 To understand their broader
synergistic effects on TH2 cell function, we investigated the
transcriptional responses to LTE4 or PGD2 added either alone
or in combination by using RNAmicroarrays. Three experimental
replicates were prepared for each of the 4 groups (control, LTE4,
PGD2, and their combination). The concentrations of LTE4 (50
nmol/L) and PGD2 (100 nmol/L) used for the treatments were
close to their relative median effective concentration values for
type 2 cytokine production in TH2 cells.
17
The data showed broad transcriptional changes after treatment.
The mRNA levels of 1344, 4750, and 5868 genes were
significantly (P < .05) modulated (including upregulation and
downregulation) by LTE4, PGD2, or their combination, respec-
tively (Fig 1, A). The effect of PGD2 was much broader than
that of LTE4. Although some (approximately 675) of the gene
responses overlapped, most of them were regulated distinctly:
669 only by LTE4 and 4075 only by PGD2. The combination of
LTE4 and PGD2 amplified significantly the range of the transcrip-
tional response. Expression of a group of 1885 genes was altered
only by combination treatment, indicating the combinatorial
effect of PGD2 and LTE4 on gene expression. Among the
modulated genes, about half were upregulated and half were
downregulated (Fig 1, B).
The genes regulated included those involved in the pathways
critical for T-cell intrinsic functions and interactions with other
cell types (through cell-surface receptors and secretedmediators).
To define the significance of the gene expression changes
specifically in relation to TH2-mediated allergic inflammation,
we analyzed first the effect of lipid mediators on T-cell intrinsic
functions and then the effect on cytokine-driven crosstalk with
downstream effector cells.Effects of PGD2 and LTE4 on the apoptosis and
migration of TH2 cells
Ingenuity pathway analysis of the microarray data suggested
that PGD2 and LTE4 treatment altered the expression of clusters
of genes associated with distinct cell-signaling pathways in
TH2 cells, including the phosphoinositide 3-kinase (PI3K)
and apoptosis pathways (see Fig E2 in this article’s Online
Repository at www.jacionline.org). Western blotting for
phospho-Akt also confirmed that activation of the PI3K pathway
by PGD2 and LTE4 was inhibited by TM30089 and montelukast
(see Fig E3 in this article’s Online Repository at www.
jacionline.org). PI3K pathway signaling is critical in mediatingthe antiapoptotic and chemotactic roles of PGD2/CRTH2.
12,22
Therefore we further addressed the effect of PGD2, LTE4, and
their combination on these functions (Fig 2).
In the case of apoptosis, both PGD2 and LTE4 markedly
reduced upregulation of Annexin V in TH2 cells after 16 hours
of IL-2 withdrawal (Fig 2, A). The combination of 2 mediators
additively enhanced this effect.
In chemotaxis assays we first compared the chemotactic effect
of PGD2 with that of cysLTs, including LTD4 and LTE4 (Fig 2, B,
left panel). These induced migration in a dose-dependent manner,
peaking around 30 nmol/L for PGD2 and LTE4 and 20 nmol/L for
LTD4. The maximum response achieved by LTE4 was higher
(approximately 2-fold) than that elicited by LTD4 but only
approximately 27% of that elicited by PGD2. The combination
of PGD2 and LTE4 at concentrations close to their median
effective concentration synergistically enhanced cell migration
(Fig 2, B, right panel).
In both apoptosis and chemotaxis assays the contribution of
PGD2 and LTE4 was ablated by TM30089 and montelukast,
respectively, and the combination of TM30089 and montelukast
inhibited almost all cell responses induced by the combination
of PGD2 and LTE4.
FIG 2. Effects of PGD2 and LTE4 on the apoptosis andmigration of TH2 cells.A,Detection of Annexin V in TH2
cells treated with IL-2 deprivation in the presence of compounds, as indicated. B, Cell migration in response
to PGD2, LTE4, or LTD4 (left panel) or the combination of indicated compounds (right panel). *P < .05
between indicated treatments (Fig 2, A) or between PGD2 plus LTE4 and other treatments (Fig 2, B). n 5 3.
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 5
XUE ET AL 1361Effects of PGD2 and LTE4 on expression of adhesion
molecules in TH2 cells
Inspection of the microarray data indicated induction by PGD2
and LTE4 of a particularly large number of transcripts associated
with leukocyte adhesion (Table I). Prominent among these were
the integrins aV (ITGAV), a2 (ITGA2), aE (ITGAE), and a11
(ITGA11), which constitute subunits of the leukocyte receptors
a2bL for intercellular adhesion molecule 1 (ICAM-1) on
endothelium, aEb7 for E-cadherins on epithelium, and a2b/
aVb3 for collagen and vitronectin in tissue extracellular matrix.
In addition, PGD2 and LTE4 induced expression of transcripts
encoding ICAM-1 (ICAM1) and ICAM-2 (ICAM2), as well as
the homophilic adhesion molecule CD31 (PECAM1) and the
cadherin/catenin protein family members CTNNAL1, CTNNA1,
CTNND1, PCDHA1, PCDHA4, and CDH1, which also act as
homophilic adhesion receptors. The majority of these genes
(n 5 14) were induced by PGD2 alone, whereas only 3 (ITGAV,
CTNND1, and ITGA11) were induced by LTE4. Upregulation of
some genes (IGSF3, CTNNA1, NINJ1, DCHS1, PCDHA4, and
ITGA2) was amplified by the combination of PGD2 and LTE4.
To explore the consequences of such increased integrin
expression on TH2 cell-cell adhesion, we used an in vitro cell
activation–induced aggregation (CAIA) assay.23 Stimulation
with either lipid alone caused marked CAIA that formed within
0.5 and 1 hours and persisted for 4 to 6 hours (Fig 3, A). The com-
bination of both mediators further enhanced the aggregation. To
verify the involvement of integrins, which are critically dependent
onCa21 ions, we tested the effect of EDTA, an inhibitory chelating
agent, and MnCl2, an activator of integrin function, on PGD2/
LTE4-induced CAIA. As shown in Fig 3, B, EDTA (5 mmol/L)inhibited and MnCl2 (1 mmol/L) prolonged the CAIA. Blocking
antibodies to CD54 (ICAM1) and CD31 (PECAM1) were used to
further confirm the contribution of integrins to the CAIA (Fig 3,
C). Both antibodies partially reduced the intensity of CAIA in a
concentration-dependent manner. The inhibitory effect of
anti-CD54 was slightly more potent than that of anti-CD31, and
the combination showed a marginal additive effect.
Enhancement of proinflammatory protein
production by PGD2 and LTE4 in TH2 cells
To focus on gene regulation potentially relevant to T cell–
mediated diseases, we next analyzed the genes encoding cytokines,
chemokines, their receptors, and cluster of differentiation (CD)
molecules detected by the microarray (Fig 4). A total of 95 of these
genes were significantly modulated, most of them upregulated (Fig
4, A, and see Table E2 in this article’s Online Repository at www.
jacionline.org), most significantly the cytokines and chemokines.
Although some of these effects were induced by PGD2 alone (eg,
IL26, IL1RL1, and CCR4) or LTE4 alone (eg, CCL3, CCL3L1,
CCL3L3, and CCL4L2), most were driven by their combination.
In addition to type 2 cytokine genes, the expression of many other
genes was also synergistically enhanced by the combination treat-
ment (Fig 4, B). A number of genes were downregulated (see
Table E2), notably transcription of GPR44, the gene for CRTH2
(CD294), which was downregulated by 2.4-fold by PGD2 alone
and 3.8-fold by combination treatment. Importantly, these microar-
ray datawere largely confirmed also by using a PCR array assay for
human common cytokines, including 84 cytokine genes, among
which approximately 30 showed significant changes (see Table
E3 in this article’s Online Repository at www.jacionline.org),
TABLE I. List of genes encoding adhesion molecules upregu-
lated by PGD2, LTE4, or their combination in TH2 cells detected
by using a microarray*
Gene Protein
Sample treatment
PGD2 LTE4 PGD2 1 LTE4
FBLN7 Fibulin 7 11 1 11
IGSF3 Immunoglobulin superfamily,
member 3
1 11
CTNNAL1 Catenin alpha-like 1 11 11
CTNNA1 Catenin alpha-1 1 1 11
NINJ1 Ninjurin-1 1 11
CEACAM1 CD66a 1 1
PECAM1 Platelet endothelial cell
adhesion molecule
1 1 1
CD226 CD226 molecule 1 1 1
CD9 CD9 molecule 1 1 1
DCHS1 Dachsous 1 1
ICAM1 CD54 1 1
PCDHA4 Protocadherin alpha-4 1
LAMA5 Laminin, alpha 5 1 1
SELE E-selectin 1
ITGAV Integrin alpha-V 1 1
ITGAX CD11c 1 1
CD44 CD44 molecule 1 1
ITGA2 CD49b 1
ITGB1BP1 Integrin beta-1–binding
protein 1
1 1
CTNND1 Catenin delta-1 1 1
ICAM2 CD102 1
CIB2 Calcium and integrin binding
family member 2
1
PCDHA1 Protocadherin alpha-1 1
CD151 CD151 molecule (Raph blood
group)
1
ITGAE Integrin, alpha E 1
CDH1 Cadherin-1 1
ITGA11 Integrin alpha-11 1
11, Fold change greater than 3.
*The concentrations of PGD2 and LTE4 were 100 and 50 nmol/L, respectively.
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the PCR array (Fig 4, C).
To further verify our findings, we also conducted qPCR (Fig 5,
A) and Luminex (Fig 5, B) assays on selected cytokines. The
qPCR data strongly supported the synergistic effects of PGD2
and LTE4. At the protein level, combination treatment either
additively (IL-3, IL-22, and macrophage colony-stimulating
factor) or synergistically (IL-8, IL-9, IL-21, and GM-CSF)
enhanced the cytokine production. A similar cytokine profile
was also observed after stimulation with phorbol 12-myristate
13-acetate (PMA)/ionomycin in both cultured TH2 cells (by
means of intracellular cytokine staining) and ex vivo TH2 cells
(by means of qPCR/Luminex; see Fig E1, B and C). As expected,
TM30089 or montelukast only partially inhibited cytokine
upregulation after PGD2 plus LTE4, but a combination of
TM30089 and montelukast completely blocked this effect (see
Fig E4 in this article’s Online Repository at www.jacionline.org).Effect of cytokines induced by PGD2 and LTE4 from
TH2 cells on neutrophil function
Neutrophilia is detected in the majority of patients with severe
asthma,19 and the cytokines induced by activation of TH2 cellsincluded several that could potentially interact with neutrophils.
To explore this possibility, we tested the ability of IL-8 and
GM-CSF produced by TH2 cells to elicit relevant changes in hu-
man neutrophil behavior (Fig 6). As indicated by the data in Fig 6,
A, treatment with PGD2 and LTE4 promoted secretion of IL-8 and
GM-CSF from resting levels (<90 and <70 pg/mL, respectively, in
supernatant 1 to more than 560 and 650 pg/mL, respectively, in
supernatant 2; Fig 6, A). This was inhibited by coincubation
with TM30089 and montelukast (approximately 94 pg/mL IL-8
and approximately 50 pg/mL GM-CSF in supernatant 3).
First, we addressed the effect of endogenous IL-8 on neutrophil
chemotaxis. Recombinant IL-8 induced neutrophil migration
with a typical chemotaxis dose curve (see Fig E5, A, in this
article’s Online Repository at www.jacionline.org). This effect
could be inhibited by a neutralizing antibody against IL-8 in a
dose-dependent manner (see Fig E5, B). The TH2 supernatant
containing high levels of IL-8 (supernatant 2) had a strong
capacity to induce neutrophil migration (Fig 6, B, left panel).
Inhibition of IL-8 production by TM30089 and montelukast
caused substantial (approximately 43%) reduction of the
chemotactic activity of supernatant 3. The neutrophil migration
to supernatant 2 was mostly blocked by IL-8 neutralizing
antibody. To rule out the possibility that cell migration was
induced directly by PGD2 or LTE4 (used to prepare supernatant
2), we examined the effects of these mediators (Fig 6, B, right
panel). Neither was chemotactic for neutrophils.
Next, we studied the influence of endogenous GM-CSF on
neutrophil behavior by measuring its ability to rescue cells from
serum starvation–induced apoptosis using CD16 (FcgRIII)
expression as a biomarker of cell integrity (see Fig E6, A, in
this article’s Online Repository at www.jacionline.org).24 Con-
firming the validity of the assay, the numbers of CD16high neutro-
phils decreased after serum withdrawal, which was inhibited by
recombinant GM-CSF in a dose-dependent manner (see Fig E6,
B). The inhibitory effect of GM-CSF was reversed by a neutral-
izing antibody against human GM-CSF (see Fig E6, C). Impor-
tantly, similar protection against apoptosis was observed when
TH2 cell supernatants, particularly supernatant 2, were substituted
for recombinant GM-CSF (Fig 6,C, left panel). The protective ca-
pacity depended on the level of GM-CSF in the supernatant,
which was reduced either by the inhibition of GM-CSF produc-
tion in TH2 culture (supernatant 3) or GM-CSF neutralizing
antibody. To further confirm the antiapoptotic activity of the
endogenous GM-CSF induced by PGD2 and LTE4, we also
examined the expression of Annexin V in neutrophils (Fig 6, C,
right panel). As expected, TH2 supernatants, especially superna-
tant 2, reduced the numbers of Annexin V–positive cells
markedly, whichwas partially inhibited by theGM-CSF antibody.DISCUSSION
TH2 cells play an important role in type II immunity, particu-
larly in mast cell–mediated allergic responses, by releasing high
levels of type 2 cytokines.25 Our previous study demonstrated
that PGD2 and cysLTs are the dominant mediators from activated
mast cells that induce TH2 cytokine production.
17 A combination
of these mediators, particularly PGD2 and LTE4, synergistically
enhances this response. In this study we further explored the
role of PGD2 and LTE4 and their synergistic effect on diverse
TH2 cell functions and revealed that the proinflammatory effects
of these mediators are broader than previously recognized.
FIG 3. Involvement of integrins in CAIA of TH2 cells induced by PGD2 and LTE4. Cell aggregation after
incubation with indicated treatments for 2 hours (A), for 2 or 9 hours in the presence of EDTA or MnCl2
(B), or for 1 hour in the presence of the indicated antibodies (C). Scale bar 5 0.5 mm. *P < .05 between
PGD2 plus LTE4 and other treatments or between indicated conditions (n 5 2-5).
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tor, gene expression was widely regulated; a number of cytokines,
chemokines, and adhesion molecules were upregulated; and
several cell-signaling pathways associated with cell adhesion
and migration and apoptosis were activated. The upregulated cy-
tokines and other proteins were functional to amplify proinflam-
matory responses of both TH2 cells themselves and downstream
effectors. Combinations of PGD2 and LTE4 showed synergistic
effects on these responses. Our findings provide novel insight
into the critical role of PGD2 andLTE4,which contribute to impor-
tant aspects of mast cell/TH2 cell–mediated allergic disorders.
Both PGD2 and LTE4 are lipid mediators involved in a wide
range of chronic inflammatory disorders, including allergic
asthma and rhinitis.26,27 Bronchoalveolar lavage fluid PGD2 and
urinary LTE4 levels are increased in asthmatic patients. The
role of PGD2 has been well studied, but the role of LTE4 and
the molecular mechanisms used by these mediators are still
obscure.10-12 For the first time, we show microarray analysis ofthe effects of these mediators in human TH2 cells, which
suggested that their effects are not limited to type 2 cytokines
but rather include a broad range of different genes. In general,
the responses to PGD2 were more pronounced than those to
LTE4. Although many genes are regulated by both lipids, these
lipids seem to use different signaling mechanisms because most
genes detected in the microarray were regulated distinctly.
However, these mechanisms interact with each other because
the combination of the lipids enhances gene regulation through
both the intensity and number of genes. Although it has been
reported that LTE4 activates the extracellular signal-regulated
kinase pathway in human mast cells,28 no phosphorylation
of extracellular signal-regulated kinase was detected in
PGD2-activated TH2 cells.
24 Intriguingly, the microarray data in
this study indicate that the PI3K pathway is involved in both
responses. Therefore further studies will be required to
understand how the signals from these lipids interact to
synergistically amplify their proinflammatory effects.
FIG 5. Effects of PGD2 and LTE4 on production of selected cytokines in TH2
cells.A, Levels of mRNAmeasured by using qPCR. ThemRNA levels in con-
trol samples were treated as 1-fold. B, Protein levels were detected with the
Luminex assay. *P < .05 between PGD2 plus LTE4 and other conditions or
the indicated condition (n 5 3).FIG 4. PGD2 and LTE4 modulate gene transcription of cytokines,
chemokines, and surface receptors in TH2 cells determined by means of
microarray (A and B) or PCR array (C). Fig 4, A, Venn diagram and heat
map showing the number and distribution of genes significantly regulated.
Fig 4, B and C, Strongly upregulated genes. P < .05 (n 5 3).
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ized by production of high levels of type 2 cytokines that in
turn promote type 2 responses in patients with allergic diseases.
A subset of TH2 cells (CD4
1CRTH21CCR61RORgt1) can
also produce IL-17.29 In this studywe demonstrated that TH2 cells
activated by PGD2/LTE4 and other stimulations, such as PMA/
ionomycin, could producemany other proinflammatory cytokines
and chemokines that could also play important roles in orches-
trating TH2-mediated immune responses. IL-8 and CCL3 are
potent chemokines for neutrophils,30 a cell type that is associated
with severe asthma.18,19 IL-8 is likely also secreted from other
cell types in asthmatic patients, including bronchial epithelial
cells. IL-21 is involved in allergic disorders, controlling the
differentiation and function of T and B cells.31 IL-22, an IL-10
family cytokine expressed by cell types, including TH17, TH22,
gd T cells, natural killer, and group 3 innate lymphoid cells, is
bifunctional, with both proinflammatory and protective
effects on tissues depending on the inflammatory context. IL-
22–producing cells and plasma concentrations of IL-22 are
increased with the severity of atopic dermatitis and asthma.32,33GM-CSF is critical for granulocyte survival and enhances their
activities.34 Increases in GM-CSF levels are detected in patients
with allergic asthma, and anti–GM-CSF antibodies administered
during allergen challenge of sensitized mice inhibited airway
inflammation and mucus production.35 Our data also confirmed
that the cytokines induced by PGD2 and LTE4 from TH2 cells
are functional, suggesting that these cytokines could make an
important contribution to the downstream effects of TH2 cell
activation. The tested cytokines (IL-8 and GM-CSF) potently
promoted neutrophil activation, although neutralizing antibodies
against these cytokines could not completely inhibit the
neutrophil activation in response to TH2 supernatants, indicating
other products, such as CCL3, might also contribute.
It has been recognized that numbers of neutrophils, as well as
eosinophils, are increased in the sputum of patients with severe
persistent asthma.19,36,37 The interaction between TH2 cells and
eosinophils through type 2 cytokines has been well established.
Here we reveal novel mechanisms linking TH2 activation and
neutrophilia. Considering that upregulation of the PGD2 pathway
and CRTH2 levels is also linked with severe and poorly controlled
asthma,27 PGD2/CRTH2 might contribute to severe asthma
through neutrophil recruitment and activation. A contribution of
PGD2/CRTH2 to neutrophilic inflammation has also been
FIG 6. TH2-derived cytokines activate neutrophils. A, IL-8 and GM-CSF levels in stimulated TH2 cell
supernatants assigned as supernatants 1 (white bars), 2 (gray bars), and 3 (black bars, n 5 4). B, Effect of
supernatants (left panel), IL-8, PGD2, LTE4 (right panel), and anti–IL-8 antibody on neutrophil migration.
C, Effect of supernatants and anti–GM-CSF antibody on expression of CD16 (left panel) and Annexin V
(right panel) in neutrophils determined by using fluorescence-activated cell sorting. *P < .05 between the
indicated treatment and other conditions (n 5 2-7).
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hypersensitivity–induced skin neutrophil inflammation in the
mouse.38
TH2 cells are enriched at the site of allergic inflammation, but
the mechanism involved in recruitment of the cells remains
obscure. Immune cells undergo a series of sequential steps during
extravasation from blood to tissue, including tethering, rolling,
adhesion, crawling, and transmigration.39 Our data suggested
that PGD2 and LTE4 contribute to the TH2 recruitment cascade
through promoting selectin-mediated rolling and integrin-
dependent adhesion. Several adhesion molecules could enhance
this because antibodies to CD54 and CD31 only partially reduced
CAIA. The present study demonstrated the important roles of
PGD2 and LTE2 in the TH2 cell infiltration seen during allergic
inflammation.
The effect of PGD2 on TH2 cells is mediated by CRTH2
because it can be completely abolished by a selective CRTH2
antagonist but not by the inhibitor of D prostanoid receptor 1.11
The receptor mediating the biological activities of LTE4 is still
uncertain, although CysLT1 and CysLT2 are both expressed by
human TH2 cells and the effects of cysLTs, including LTE4, can
be inhibited by the CysLT1 antagonist.
16,17 The activity of LTE4is unlikely to be mediated by these receptors because of their
low affinity for this leukotriene compared with LTD4 and
LTC4.
13,14 The CysLT1-mediated calcium flux in response to
cysLTs in human TH2 cells showed a rank order of potency as
follows: LTD4 > LTC4 > LTE4.
16 However, the proinflammatory
efficacy of LTE4, used alone or in combination with PGD2, is
much higher than that of LTD4 and LTC4.
17 LTE4 can also
stimulate inflammatory responses through mechanisms
independent of CysLT1 or CysLT2.
28,40 It has been proposed
that both montelukast and LTE4 can interact with P2Y-like
receptors41,42; however, P2Y12 activation is undetectable in TH2
cells.16,17 Therefore it is possible that the effect of LTE4 is
mediated by a montelukast-sensitive receptor that is distinct
from the established cysLT receptors.
In summary, this study highlights the broad proinflammatory
functions of PGD2 and cysLTs, particularly LTE4, in TH2 cells.
They combine to upregulate the expression ofmany proinflamma-
tory molecules, promote cell adhesion and migration, suppress
cell apoptosis, and induce neutrophil activation. These
observations indicate how these 2 mast cell products can promote
allergic responses and point to potential improved therapies for
allergic inflammation.
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Key messages
d The effect of PGD2 and LTE4 on activation of TH2 cells is
much broader than previously recognized, which might
contribute to the etiology of IgE/mast/TH2 cell–mediated
allergic inflammation.
d The combination of PGD2 and LTE4 synergistically en-
hances proinflammatory responses in TH2 cells.
d The combination of PGD2 and LTE4 promotes TH2 cell/
neutrophil crosstalk.
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METHODS
Reagents
PGD2 and LTE4 were purchased from Enzo Life Science (Farmingdale,
NY). TM30089 was supplied by ChemieTek (Indianapolis, Ind). The human
CD41 TCell Isolation Kit II, anti-human CRTH2MicroBead Kits, T-cell acti-
vation/expansion kits, and anti-human CRTH2 antibody were from Miltenyi
Biotec (Bergisch Gladbach, Germany). X-VIVO 15 medium was purchased
fromLonza. AIMVmediumwas purchased from Invitrogen (Carlsbad, Calif).
HBSS was from Gibco (Carlsbad, Calif). Ficoll-Paque Plus was supplied by
GE Healthcare (Pittsburgh, Pa). Lymphoprep was purchased from
Axis-Shield UK (Dundee, United Kingdom). The RNeasy Mini kit and
Omniscript Reverse Transcription kit were supplied from Qiagen. Real-time
qPCR Master Mix and probes were from Roche. Primers were synthesized
by Eurofins MWG Operon (Ebersberg, Germany). Human rIL-8, anti–IL-8,
and anti-CD54 (ICAM-1) antibodies were purchased from R&D Systems.
Anti-CD31 (PECAM-1) antibody was from Thermo Fisher Scientific
(Waltham, Mass). Anti-human GM-CSF, CD3, CD4, CCR6, CCR7,
CD45RO, IL-4, IL-5, IL-8, IL-13, and IFN-g antibodies and Annexin
V–allophycocyanin were obtained from BioLegend (San Diego, Calif).
Anti-human CD16, IL-22, and GATA3 antibodies and the viability dye eFluor
780 were from eBioscience (San Diego, Calif). Anti-human RORgt antibody
was from BD Biosciences. Human rIL-2, human rIL-4, and human rGM-CSF
were from PeproTech (Rocky Hill, NJ). Other chemicals were from
Sigma-Aldrich (St Louis, Mo).
TH2 cell preparation
Human CD41CRTH21 TH2 cells were prepared, as described in our
previous reports.E1 Briefly, PBMCs were isolated from buffy coats by using
Ficoll-Paque Plus density gradient centrifugation, followed by CD41 cell
purificationwith theMACSCD41TCell IsolationKit II. After a 7-day culture
in AIM V medium containing 10% human serum, 50 U/mL rhIL-2, and 100
ng/mL rhIL-4, CRTH21 cells were isolated from the CD41 culture by means
of positive selection with the anti-human CRTH2 MicroBead Kit. The
harvested CD41/CRTH21 cells were treated as TH2 cells and further
amplified in X-VIVO 15 medium containing 10% human serum and
50 U/mL rhIL-2 before use. For ex vivo TH2 cells, CRTH2
1 cell isolation
was directly conducted after CD41 cell purification without culture.
Flow cytometric analysis for TH2 cell phenotype
For surface marker staining, TH2 cells or PBMCs from fresh blood were
fluorescently labeled with antibodies to CD3, CD4, CRTH2, CCR6, CCR7,
CD45RA, and CD45RO in PBS containing 0.2% BSA and 2 mmol/L EDTA
and then fixed with 2% formaldehyde. Transcription factor staining was
conducted in permeabilization buffer with 0.05% saponin-containing
antibodies to GATA3 and RORgt. For analysis of intracellular cytokines,
TH2 cells were stimulated with PMA (5 ng/mL) and ionomycin
(500 ng/mL) for 4 to 5 hours. Brefeldin A (5 mg/mL) was added at 30 minutes
after starting stimulation. Then the cells were stained in a permeabilization
buffer containing antibodies to IFN-g, IL-4, IL-5, IL-8, IL-13, and IL-22.
Nonstimulated cells were used as a negative control, and dead cells were
excluded by using the viability dye eFluor 780. After staining, the cells
were acquired with an LSR II Flow Cytometer (BD Biosciences).
Western blotting
TH2 cells were treated for 15 minutes. Cell lysis and Western blotting
were performed, as described previously.E2 Briefly, the cells were
solubilized in lysis buffer (20 mmol/L Tris-HCl [pH 7.4], 250 mmol/L
sucrose, 1 mmol/L EDTA, 1 mmol/L ethyleneglycol-bis-[b-aminoethy-
lether]-N,N,N9,N9-tetraacetic acid, 1 mmol/L sodium orthovanadate,
10 mmol/L sodium glycerophosphate, 50 mmol/L sodium fluoride, 5
mmol/L sodium pyrophosphate, 0.1% 2-mercaptoethanol, protease inhibitor
mixture, and 1% Triton X-100). The samples were fractionated by using
SDS-PAGE and then electrophoretically transferred to a nitrocellulose
membrane and probed with antibodies, as indicated in the Results section.
The intensity of immunopositive bands was quantified by using ImageJ
software (National Institutes of Health, Bethesda, Md).
Quantification of cell aggregates
Briefly, cell clumps were identified by using the Otsu method of
thresholding. The intensity and size of identified objects were measured.
Results are reported as integrated intensity.
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FIG E1. Analysis of cell phenotype. A and B, Expanded TH2 cells were CD3
1CD41CRTH21CD45RO1
GATA31CCR62CCR72CD45RA2RORgt2 effector memory cells (Fig E1, A), which produce the type II
cytokines IL-8 and IL-22 after stimulation with PMA (5 ng/mL) and ionomycin (500 ng/mL; Fig E1, B), as
detected by means of flow cytometry. Blue lines represent staining of indicated cell markers, and red lines
represent unstained controls. C, The same cytokine profile was observed in freshly isolated ex vivo TH2 cells
by using qPCR (mRNA) and Luminex (protein) assays (high background IL-8 levels in the unstimulated
sample precluded accurate analysis of this cytokine in the Luminex assay; n 5 6 for Fig E1, A and B;
n 5 2 for mRNA and n 5 1 for protein in Fig E1, C).
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FIG E2. Network diagram of genes depicting pathways involved in activation of TH2 cells induced by PGD2
and LTE4 based on microarray data. A, PI3K pathway. B, Apoptosis pathway. Red color shows gene upre-
gulation, and green color shows downregulation.
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FIG E3. Phosphorylation of Akt in TH2 cells after treatment with PGD2 and
LTE4 in the presence or absence of TM30089 andmontelukast. The intensity
of the bands for phospho-Akt was quantified after normalization with the
bands for total Akt.
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FIG E4. Effect of TM30089 and montelukast on transcriptional regulation of
cytokine genes induced by PGD2 and LTE4 in TH2 cells determined by using
qPCR. The control sample was treated as 1-fold (n 5 1).
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FIG E5. Effect of IL-8 on neutrophil migration. A, Neutrophil migration to various concentrations of rhIL-8 in
chemotaxis assay. B, Effect of increasing concentration of anti–IL-8 antibody on neutrophil migration
induced by 50 nmol/L rhIL-8.
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FIG E6. Effect of GM-CSF on the decrease in CD16 levels in neutrophils, a biomarker of apoptosis, induced
by serum deprivation. A, Decrease of CD16high neutrophils with the time of serum deprivation. B, Inhibitory
effect of various concentration of rhGM-CSF on the decrease of CD16high neutrophils induced by serum
deprivation for 12 hours. C, The inhibitory effect of rhGM-CSF (1 ng/mL) was reversed by anti–GM-CSF anti-
body in a dose-dependent manner. IC50, Inhibitory concentration of 50%.
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TABLE E1. Primers and probes used for qPCR
Gene Primer Probe no.
IL3 59-TTGCCTTTGCTGGACTTCA-39
59-CTGTTGAATGCCTCCAGGTT-39
60
IL8 59-AGACAGCAGAGCACACAAGC-39
59-ATGGTTCCTTCCGGTGGT-39
72
IL9 59-CTTCCTCATCAACAAGATGCAG-39
59-AGAGACAACTGGTCACATTAGCAC-39
59
IL21 59-AGGAAACCACCTTCCACAAA-39
59-GAATCACATGAAGGGCATGTT-39
7
IL22 59-CAACAGGCTAAGCACATGTCA-39
59-ACTGTGTCCTTCAGCTTTTGC-39
6
CSF1 59-GCAAGAACTGCAACAACAGC-39
59-ATCAGGCTTGGTCACCACAT-39
19
GMCSF 59-TCTCAGAAATGTTTGACCTCCA-39
59-GCCCTTGAGCTTGGTGAG-39
1
GAPDH 59-AGCCACATCGCTCAGACAC-39
59-GCCCAATACGACCAAATCC-39
60
CSF1, Macrophage colony-stimulating factor 1.
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TABLE E2. List of cytokines, chemokines, their receptors, and CDmolecule genes regulated by PGD2, LTE4, or their combination in
TH2 cells detected by means of microarray*
Upregulation Downregulation
Gene
Sample treatment
Gene
Sample treatment
PGD2 LTE4 PGD2 1 LTE4 PGD2 LTE4 PGD2 1 LTE4
IL1A 1 1 11 IL1F7 2
IL3 11 11 111 IL15 2 2 2
IL4 1 11 IL28B 2
IL5 111 1 111 IL29 2
IL8 11 11 111 CCL4L1 2
IL9 11 CCL28 2 2
IL13 11 1 111 CXCL16 2 2
IL16 1 1 1 IL6R 2
IL22 1 IL7R 2 2 2
IL26 111 111 IL10RB 2
IL4I1 1 IL11RA 2 2
ILF2 1 IL15RA 2
CSF1 11 1 111 CCR2 2 2 2
CSF2 111 11 111 CCR3 2 2 2
LTA 1 11 CCR7 2
TNF 1 11 CXCR4 2
TNFSF8 11 1 11 CD3D 2 2
TNFSF10 1 1 1 CD40 2
TNFSF11 1 1 11 CD47 2
TNFSF14 1 1 11 CD48 2
CCL1 1 11 111 CD79B 2 2
CCL3 11 111 CD80 2
CCL3L1 11 111 CD86 2
CCL3L3 11 111 CD99L2 2
CCL4L2 11 111 CD200R1 2 2
CCL5 1 GPR44 2 2 2
CCL15 1 1
IFNGR2 1 1 11
IL1RAP 1 1
IL1RL1 111 1 111
IL1RL2 1
IL2RB 1 1
IL2RG 1 1
IL4R 1 1
IL17RA 1 1
IL17RB 1
IL18R1 1 1 1
IL18RAP 11 11 111
IL21R 1 11
IL27RA 1 1 1
IL28RA 1
CCR4 11 1
CXCR3 1
CXCR5 1
CXCR6 1
TNFRSF8 11 11
TNFRSF9 111 11 111
CD2BP2 1 1
CD5L 1
CD9 1 1 1
CD28 1 1
CD40LG 1 11
CD44 1 1
CD52 1
CD53 1 1
CD55 1
CD58 1 1
CD59 1
CD69 11 11 111
(Continued)
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TABLE E2. (Continued)
Upregulation Downregulation
Gene
Sample treatment
Gene
Sample treatment
PGD2 LTE4 PGD2 1 LTE4 PGD2 LTE4 PGD2 1 LTE4
CD70 1
CD81 1
CD82 1 1 1
CD83 1 11
CD84 1 1
CD109 1 11
CD151 1
CD200 1
CD226 1 1
CD276 1 1
CSF, Macrophage colony-stimulating factor.
11 or 2 2, Fold change of 3 or greater; 111, fold change of 6 or greater.
*Concentrations of PGD2 and LTE4 were 100 and 50 nmol/L, respectively.
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TABLE E3. List of cytokine genes regulated by PGD2, LTE4, or their combination in TH2 cells detected by means of PCR array*
Upregulation Downregulation
Gene
Sample treatment
Gene
Sample treatment
PGD2 LTE4 PGD2 1 LTE4 PGD2 LTE4 PGD2 1 LTE4
IL3 1 11 111 BMP4 2 2 2
IL5 11 11 111 BMP8B 2 2 2
IL8 11 1 111 GDF9 2 2 2
IL9 1 1 111 IFNA5 2 2 2
IL10 1 1 11 IFNK 2 2 2 2
IL13 1 1 11 IL15 2 2 2
IL21 1 11 111 IL17C 2 2 2
IL22 1 11 111 IL18 2 2 2
CSF1 1 1 11 IL24 2 2 2
CSF2 11 11 111 NODAL 2 2 2 2
FASLG 11 1 11 TGFB3 2 2 2
LTA 1 1 11 TNFSF13B 2 2 2 2 2
PDGFA 11 1 11
TNF 1 1 1
TNFSF8 1 1 11
TNFSF10 1 1 1
TNFSF11 11 1 11
TNFSF14 1 1 1
CSF, Macrophage colony-stimulating factor.
11 or 2 2, Fold change of 3 or greater; 111, fold change of 6 or greater.
*Concentrations of PGD2 and LTE4 were 100 and 50 nmol/L, respectively.
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